The US Biomedical Advanced Research and Development Authority (BARDA) and Regeneron Pharmaceuticals have partnered to develop a pair of antibodies to prevent and treat Middle East Respiratory Syndrome (MERS).
Phase I Clinical Trials are underway for SAB Biotherapeutics’ antibody treatment (SAB-301) for Middle East Respiratory Syndrome.
This document discusses the efficacy of ciprofloxacin therapy for pneumonic plague, nonclinical pharmacokinetics of ciprofloxacin and translation to human dosing, ciprofloxacin safety, and the benefit/risk of ciprofloxacin treatment of pneumonic plague.
This report addresses elements of hospital-based acute care, specifically antitoxins and intravenous antimicrobial use, and the diagnosis and management of common anthrax-specific complications during a mass-casualty incident.
Medicines for Malaria Venture distributed 400 compounds with antimalarial activity free to 200 labs in 30 countries.